直覺手術 (ISRG) 2003 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • We would like to thank all parties for holding, and to remind you we've placed your lines on listen-only until the question-and-answer segments of today's conference. This call is being recorded. Should you have any objections, please disconnect at this time.

    我們感謝各方持線,並提醒您,我們已將您的線路設定為僅收聽模式,直到今天會議的問答環節。本次通話將被錄音。如您有任何異議,請於此時中斷連線。

  • I would now like to turn the call over to today's speaker, Mr. Ben Gong (ph), VP, Treasurer and Corporate Controller. Thank you. Sir, you may begin.

    現在我想把電話交給今天的講者,Ben Gong 先生(音),副總裁、財務主管兼公司財務控制長。謝謝。先生,您可以開始了。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Hello. Welcome to Intuitive Surgical's first quarter conference call. With me today, we have Lonnie Smith, President and our CEO, Susan Barnes, our CFO, Aleks Cukic (ph), our VP Business Development and Strategic Planning, David Shaw, our VP Legal Affairs and Corporate Counsel, and Fred Moll, our co-founder and Medical Director.

    您好。歡迎參加 Intuitive Surgical 第一季電話會議。今天與我一同出席的有:總裁暨執行長 Lonnie Smith、財務長 Susan Barnes、副總裁(業務發展與策略規劃)Aleks Cukic(音)、副總裁(法務事務與公司法律顧問)David Shaw,以及共同創辦人兼醫療總監 Fred Moll。

  • Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's SEC filing. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

    在開始之前,我想提醒各位,今天通話中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在公司向 SEC 提交的文件中詳細說明。提醒潛在投資人勿過度依賴此類前瞻性陳述。

  • Please note that this conference call will be available for audio replay on our website at www.IntuitiveSurgical.com, on the audio archive section of our investor relations page. In addition, today's press release is posted to our website. We'd like you to read our press release and all other SEC filings mentioned in that release.

    請注意,本次電話會議將可於我們網站 www.IntuitiveSurgical.com 的投資人關係頁面之音訊存檔區提供重播。此外,今天的新聞稿亦已張貼於我們網站。我們希望您閱讀該新聞稿以及其中提及的所有其他 SEC 申報文件。

  • Today's format will consist of providing you with highlights for the first quarter, as derived in our press release, announced earlier today, followed by a question-and-answer session. First, Lonnie will present business highlights of the first quarter. Susan will follow with a review of our first quarter's financial results and provide an outlook for the year. Next, Aleks will discuss sales and marketing, and finally David will update you regarding intellectual property issues. Finally, we will host a question-and-answer session. With that, I would like to introduce Lonnie Smith, our President and CEO.

    今天的流程將先提供第一季重點摘要(摘自我們於今日稍早發布的新聞稿),接著進行問答。首先,Lonnie 將介紹第一季的業務重點。接著 Susan 將回顧第一季財務結果並提供全年展望。然後 Aleks 將討論銷售與行銷,最後 David 將就智慧財產權議題提供最新進展。最後,我們將進行問答環節。接下來,我想介紹我們的總裁暨執行長 Lonnie Smith。

  • Lonnie Smith - President and CEO

    Lonnie Smith - President and CEO

  • Thank you, Ben. I'd like to thank each of you for taking the time to join us for today's conference call. First, I would just like to say that I'm delighted David [Shaw's] quarterly update on the status of litigation with Computer Motion is no longer necessary. However, David will give a brief update on the [Wilke] litigation.

    謝謝你,Ben。感謝各位撥冗參加今天的電話會議。首先,我想說,我很高興 David [Shaw] 關於與 Computer Motion 訴訟狀態的季度更新已不再需要。不過,David 仍會就 [Wilke] 訴訟提供簡要更新。

  • Having said that, I'll begin with the highlights of the first quarter. During the quarter, total revenue grew to $19.2 million, up 33% from prior year. Recurring revenue grew to $5.4 million-up 103% from prior year-comprising 28% of total revenue.

    話不多說,我先從第一季重點開始。本季總營收成長至 1,920 萬美元,較去年同期成長 33%。經常性收入成長至 540 萬美元——較去年同期成長 103%——占總營收的 28%。

  • We shipped 14 [da Vinci] Surgical Systems, and end the quarter with 163 systems installed worldwide. We continued to make progress in our financial metrics during the quarter. Our gross profit margin improved to 54.6%, from 47.9% in the first quarter of last year.

    我們出貨 14 套 [da Vinci] 手術系統,季末全球安裝量達 163 套。本季我們在財務指標方面持續取得進展。毛利率由去年第一季的 47.9% 提升至 54.6%。

  • Our first quarter net loss was $2.3 million-down from a loss of $5.6 million-representing a 59% improvement from the first quarter of last year, and down $300,000 from last quarter, as we drive toward profitability at the end of this year.

    第一季淨損為 230 萬美元,較 560 萬美元的淨損縮小,較去年第一季改善 59%;並較上季減少 30 萬美元,因我們正朝今年年底達成獲利邁進。

  • Finally, the first quarter has historically been our highest cash burn quarter. We cut our cash burn to $5.8 million from $10.1 million in the first quarter of last year. We ended the quarter with $45 million in cash.

    最後,第一季歷來是我們現金消耗最高的季度。我們將現金消耗由去年第一季的 1,010 萬美元降至 580 萬美元。季末現金餘額為 4,500 萬美元。

  • Now, turning to operations. Our sales, service and clinical support team continue to grow systems sales on an installed-system base, and procedures as reflected by the growth in our top line. A few of the significant milestones this quarter include purchase by Hackensack University Medical Center of their third da Vinci Surgical System, and the decision to upgrade all three of their systems with a new fourth arm; the University of California Irvine's purchase of a second da Vinci system to go into their neurologic surgery training center, which is led by Dr. [Ralph Clemon], and the purchase of da Vinci Surgical Systems by two of the leading children's hospitals in the United States-Denver Children's Hospital and Arkansas Children's Hospital.

    接著談營運。我們的銷售、服務與臨床支援團隊持續在既有裝機基礎上推動系統銷售與手術量,並反映在營收成長上。本季幾項重要里程碑包括:Hackensack University Medical Center 購買其第三套達文西手術系統,並決定將其三套系統全部升級加裝新的第四支手臂;加州大學爾灣分校購買第二套達文西系統,將配置於其由 [Ralph Clemon] 醫師領導的神經外科手術訓練中心;以及美國兩家領先的兒童醫院——丹佛兒童醫院與阿肯色兒童醫院——購買達文西手術系統。

  • We formed a strategic alliance with Medtronic, to advance minimally-invasive beating-heart surgery. Aleks will give you more details on the sales and marketing, and this alliance, later on this call.

    我們與 Medtronic 建立策略聯盟,以推進微創跳動心臟手術。稍後在本次通話中,Aleks 將就銷售與行銷以及此聯盟提供更多細節。

  • As we mentioned last quarter, we added a second cardiac procedure to our inter-cardiac clearance. Totally endoscopic atrial-septal defect repair for closure. Hospitals in the US can now use the da Vinci's surgical system to minimally-invasively close a hole between the chambers of a patient's heart.

    如同我們上季所提,我們在心臟適應症核准範圍中新增了第二項心臟手術。即全內視鏡心房中隔缺損修補(封堵)。美國的醫院現在可使用達文西手術系統,以微創方式封閉病患心臟腔室之間的孔洞。

  • Our engineer in the marketing team [leads] for sale the fourth arm that I mentioned earlier, with its supporting electronic hardware and software. In addition, they released several versions of vision and ease of use enhancements, including a three optical channel endoscope, a new eliminator, a bifurcated light guide, a new twist-lock [candula]. Each of these products enhance the surgical capability, ease of use, and/or performance of da Vinci Surgical Systems. We continue to make significant progress in our new 5 mm instrument architecture. We expect to release these new instruments this summer. Our operations team made excellent progress in their drive toward lean manufacturing. They achieved significant reductions in both instrument and systems cost.

    我們的工程與行銷團隊正推動我先前提到的第四支手臂銷售,並搭配其支援的電子硬體與軟體。此外,他們也推出多項視覺與易用性強化版本,包括三光學通道內視鏡、新型消除器、分叉式導光器、新的旋鎖式 [candula]。上述各項產品皆可提升達文西手術系統的手術能力、易用性及/或效能。我們在全新的 5 mm 器械架構方面持續取得重大進展。我們預期將於今年夏季推出這些新器械。我們的營運團隊在推動精實製造方面也取得極佳進展。他們在器械與系統成本兩方面都達成顯著降低。

  • On March 7th, we announced that we intend to merge with Computer Motion, to combine the strengths of both companies, to advance minimally-invasive surgery and better serve our customers. We sincerely believe that combining our highly-complementary technologies and organizational talents, we will be able to provide surgeons and hospitals with the best possible products and clinical support. This merger will also end the ongoing litigation between the companies, and will allow management to focus our time and total energy on value-creation for our customers and our shareholders. We filed our S4-our joint proxy statement and prospectus-on March 28th. We expecting to complete the merger by the end of the second quarter.

    3 月 7 日,我們宣布擬與 Computer Motion 合併,以結合兩家公司優勢,推進微創手術並更好地服務客戶。我們深信,透過整合高度互補的技術與組織人才,我們將能為外科醫師與醫院提供最佳的產品與臨床支援。此次合併也將終止雙方持續進行的訴訟,並使管理團隊能將時間與全部精力聚焦於為客戶與股東創造價值。我們已於 3 月 28 日提交 S4——我們的聯合委託書聲明與公開說明書。我們預期在第二季末前完成合併。

  • We've set three primary post-merger objectives as we prepare for the combination of our companies. The first is profitability. The second is superior products and service for our hospitals and surgeon customers and their patients. Third, a results-driven company culture in which we measure ourselves by our accomplishments.

    在為兩家公司整合做準備之際,我們設定了三項合併後的主要目標。第一是獲利。第二是為我們的醫院與外科醫師客戶及其病患提供更優異的產品與服務。第三是建立以成果為導向的公司文化,以我們的成就來衡量自己。

  • Currently, planning for the post-merger transition is underway. The companies expect to meet the $18 million in annual operating pre-tax cost savings we estimated in the S4. In order to achieve these objectives, we are analyzing possible post-merger plans to enhance the efficiency and productivity of a merged company.

    目前,併購後過渡期的規劃正在進行中。公司預期可達成我們在 S4 中估計的每年 1,800 萬美元營運稅前成本節省。為了達成這些目標,我們正在分析可能的併購後計畫,以提升合併後公司的效率與生產力。

  • While no final decisions have been made, the companies are considering various post-merger opportunities, including the consolidation of manufacturing and administrative functions at our corporate headquarters in Sunnyvale, maintaining an engineering presence at currently-existing locations, and creating a single sales-and-service force to cost-effectively serve and support our customers worldwide.

    雖然尚未做出最終決定,公司正在評估各種併購後機會,包括在我們位於 Sunnyvale 的公司總部整合製造與行政職能、在目前既有據點維持工程團隊據點,以及建立單一的銷售與服務團隊,以具成本效益的方式在全球範圍內服務並支援我們的客戶。

  • As we have previously stated, we expect to close the merger by the end of this quarter, subject of course to SEC and shareholder approvals. With that, I'll pass the time over to Susan, our CFO, who'll discuss our first quarter financial results.

    如同我們先前所述,在取得 SEC 與股東核准(當然以此為前提)後,我們預期將於本季末完成併購。接下來我把時間交給我們的財務長 Susan,由她說明第一季的財務結果。

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Thank you, Lonnie. Overall, as Lonnie mentioned earlier, we had many significant financial highlights for the quarter. Specifically, we realized $19.2 million of revenue-up 33% from our first quarter 2002. We grew recurring revenue to $5.4 million-up 103% over last year. We reduced our operating expense by $1 million sequentially, compared to Q4 of 2002. Our net loss dropped to $2.3 million, or $0.06 per share-representing our smallest quarterly loss since we started selling da Vinci Surgical Systems.

    謝謝你,Lonnie。整體而言,正如 Lonnie 先前提到的,本季我們有許多重要的財務亮點。具體來說,我們實現營收 1,920 萬美元,較 2002 年第一季成長 33%。我們將經常性收入提升至 540 萬美元,較去年成長 103%。與 2002 年第四季相比,我們的營運費用連續季減少 100 萬美元。我們的淨損降至 230 萬美元,或每股 0.06 美元——這是自我們開始銷售 da Vinci 手術系統以來最小的單季虧損。

  • Now, for the details. Our first quarter 2003 revenue was $19.2 million-up 33% from first quarter 2002 revenues; up $14.4 million. We shipped 14 da Vinci Surgical Systems during the quarter; 12 in the United States, 1 in Europe and 1 in the rest of the world. The 14 total units shipped were up 1, compared to 13 units shipped during the first quarter of 2002. We now have 2 more replacements of 163 systems; 112 in the United States, 41 in Europe, and 10 in the rest of the world.

    現在說明細節。我們 2003 年第一季營收為 1,920 萬美元,較 2002 年第一季營收成長 33%;增加 1,440 萬美元。本季我們出貨 14 套 da Vinci 手術系統;其中 12 套在美國、1 套在歐洲、1 套在世界其他地區。本季出貨總數 14 套,較 2002 年第一季出貨 13 套增加 1 套。我們目前共有 163 套系統(另有 2 套替換機);其中 112 套在美國、41 套在歐洲、10 套在世界其他地區。

  • Total Q1 2003 revenue by product group was as follows. Systems, $13.8 million. Instruments and accessories, $3.6 million. and Service, $1.8 million. Recurring revenue grew to $5.4 million in the first quarter-up 103% from the $2.7 million during the first quarter of last year, and up 15% sequentially from the $4.7 million we earned last quarter.

    2003 年第一季按產品群組劃分的總營收如下。系統:1,380 萬美元。器械與配件:360 萬美元。以及服務:180 萬美元。第一季經常性收入成長至 540 萬美元,較去年第一季的 270 萬美元成長 103%,並較上季我們取得的 470 萬美元連續季成長 15%。

  • We are quite pleased with our recurring revenue growth, and the fact that our recurring revenue continues to increase as a percentage of our total revenue. Recurring revenue grew to 28% of total revenue this first quarter, as compared to 19% in the first quarter of last year. Our recurring revenue continues to climb each quarter, as we place more systems and our customers perform more procedures.

    我們對經常性收入的成長感到相當滿意,也很高興經常性收入占總營收的比重持續提高。本季經常性收入占總營收比重提升至 28%,相較去年第一季為 19%。隨著我們部署更多系統、客戶執行更多手術,我們的經常性收入每季持續攀升。

  • Gross margin for the first quarter of 2003 was $54.6%, compared to 47.9% for the first quarter of 2002. First quarter 2003 gross margin improvement was driven by higher da Vinci Surgical Systems selling prices and lower product warranty costs, resulting from improved sales reliability.

    2003 年第一季毛利率為 54.6%,相較 2002 年第一季為 47.9%。2003 年第一季毛利率改善主要受 da Vinci 手術系統售價提高與產品保固成本降低所帶動,而保固成本降低源於銷售可靠性提升。

  • Total operating expenses for the first quarter 2003 were $13.6 million; up $600,000 or 5%, compared to the first quarter of 2002. Operating expenses were $1 million less than those recorded during the fourth quarter of last year. The overall decrease in expenses was due to our drive to realize greater operating efficiencies. We ended the quarter with 273 regular employees; down 18 from the previous quarter end.

    2003 年第一季總營運費用為 1,360 萬美元;較 2002 年第一季增加 60 萬美元或 5%。營運費用較去年第四季所記錄的金額少 100 萬美元。費用整體下降是因為我們致力於實現更高的營運效率。本季末我們有 273 名正式員工;較上一季季末減少 18 人。

  • SG and A expenses were $10.3 million for the first quarter of 2003; up approximately $1.4 million from the $8.8 million spend in the first quarter of 2002. The increase over the prior year was driven by growth in our field sales and customer support organization. SG and A included a $500,000 credit for an insurance recovery made to help cover the employee theft incurred last year.

    2003 年第一季銷售、一般及行政(SG&A)費用為 1,030 萬美元;較 2002 年第一季的 880 萬美元支出增加約 140 萬美元。較前一年增加主要由我們外勤銷售與客戶支援組織的擴張所帶動。SG&A 包含 50 萬美元的保險理賠回收入帳,用以協助彌補去年發生的員工竊盜損失。

  • Research and Development expense was $3.4 million for the first quarter of 2003; down approximately $800,000 from the $4.2 million in the first quarter last year. The decrease from the prior year resulted primarily from lower clinical trial activity and lower prototype acceptance.

    2003 年第一季研發費用為 340 萬美元;較去年第一季的 420 萬美元減少約 80 萬美元。較前一年下降主要是由於臨床試驗活動減少以及原型驗收降低。

  • Other Income and Expense was approximately $800,000 for Q1 2003, compared to $500,000 the first quarter of 2002, and $400,000 last quarter. The increase was due to $500,000 of gains realized during the first quarter on sales and investment securities. The remaining $300,000 of Q1 Other Income related mostly to interest earned on investments and [inaudible] the prior quarters due to lower investment balances.

    2003 年第一季其他收益與費用約為 80 萬美元,相較 2002 年第一季為 50 萬美元、上季為 40 萬美元。增加主要是因第一季出售投資證券所實現的 50 萬美元收益。第一季其餘 30 萬美元的其他收益主要與投資利息收入有關,且由於投資餘額較低,[inaudible] 低於前幾季。

  • Our net loss for the first quarter of 2003 was $2.3 million; $0.06 per share, compared to $5.6 million or $0.15 per share in the first quarter of 2002. Our Q1 net loss was 69% lower than the first quarter of 2002, and represents the lowest net quarterly loss we've reported since selling the da Vinci Surgical Systems. Our narrowing net loss reflects our progress toward achieving profitability, which we expect to have by the fourth quarter of this year.

    2003 年第一季淨損為 230 萬美元;每股 0.06 美元,相較 2002 年第一季為 560 萬美元或每股 0.15 美元。我們第一季淨損較 2002 年第一季低 69%,並且是自我們銷售 da Vinci 手術系統以來所報告的最低單季淨損。淨損收斂反映我們朝向獲利的進展,我們預期可在今年第四季達成獲利。

  • Basic and diluted shares outstanding for EPS calculations were 36.9 million shares for the first quarter of 2003, compared to 36.3 million for the same period last year. In regard to our balance sheet, we ended the quarter with $45 million in cash-down $5.8 million from the previous quarter end. The cash was used to fund our operating losses and higher accounts receivable balances.

    用於每股盈餘(EPS)計算的基本與稀釋在外流通股數,2003 年第一季為 3,690 萬股,相較去年同期為 3,630 萬股。就資產負債表而言,本季末我們持有現金 4,500 萬美元,較上一季季末減少 580 萬美元。該現金用於支應營運虧損以及較高的應收帳款餘額。

  • Our quarter-end accounts receivable balance of $[20].9 million was up $4 million from the previous quarter. Our Q1 average days sales outstanding was 98 days-up from 72 days at the end of Q4. Ending first quarter net inventory was $8.3 million-down $500,000 from the previous quarter end. Our annual inventory turns are now 4.2 compared to 4.4, ending last year.

    本季末應收帳款餘額為 $[20].9 百萬美元,較上一季增加 400 萬美元。第一季平均應收帳款週轉天數(DSO)為 98 天,高於第四季末的 72 天。第一季末淨存貨為 830 萬美元,較上一季季末減少 50 萬美元。我們的年度存貨週轉率目前為 4.2,相較去年年底為 4.4。

  • In regard to our outlook for 2003, as Lonnie has already described, we do plan to close our merger transaction with Computer Motion by the end of the second quarter. Our outlook for the combined entity is to record between $110 million and $130 million of 2003 revenue on a pro forma basis.

    關於我們對 2003 年的展望,如 Lonnie 已經說明,我們確實計畫在第二季末前完成與 Computer Motion 的併購交易。對於合併後實體的展望,我們預期以備考(pro forma)基礎認列 2003 年營收介於 1.10 億至 1.30 億美元。

  • We are targeting profitability by Q4 of this year for the combined entity, excluding amortization of intangible assets and one-time charges associated with the merger. This outlook is consistent with the guidance we gave for Intuitive Surgical as a stand-alone entity during our last quarter call.

    我們的目標是合併後實體在今年第四季達成獲利,不包含無形資產攤銷以及與併購相關的一次性費用。此展望與我們在上一季電話會議中,對 Intuitive Surgical 作為獨立實體所提供的指引一致。

  • With that, I'd like to turn it over to Aleks, who will provide a summary of our latest sales and marketing highlights.

    接下來,我想把時間交給 Aleks,由他為我們最新的銷售與行銷重點做一個摘要。

  • Aleks Cukic - VP Business Development and Strategic Planning

    Aleks Cukic - VP Business Development and Strategic Planning

  • Thank you, Susan. As Lonnie mentioned, we shipped 14 da Vinci systems during the quarter. Twelve systems were shipped to US facilities, one to Europe and one to the rest of the world. The list of placements was notable, including Vanderbilt University Medical Center, Denver Children's Hospital, Arkansas Children's Hospital, and Institut Mont [Cerise] in Paris, which is widely recognized as one of Europe's premier, minimally invasive centers. And, the Cradle, for the laparascopic radical [prostatectomy] procedure. We believe that the early enthusiasm of these new customers will translate into rapid adoption and use of the da Vinci system within prestigious hospitals.

    謝謝你,Susan。如 Lonnie 所提到的,我們在本季出貨了 14 套 da Vinci 系統。其中 12 套出貨至美國的醫療機構,1 套至歐洲,另 1 套至世界其他地區。本季的裝機名單相當亮眼,包括 Vanderbilt University Medical Center、Denver Children's Hospital、Arkansas Children's Hospital,以及位於巴黎、廣受認可為歐洲頂尖微創中心之一的 Institut Mont [Cerise]。以及 Cradle,用於腹腔鏡根治性[前列腺切除術](laparascopic radical [prostatectomy])手術。我們相信,這些新客戶的早期熱忱將轉化為在知名醫院內對 da Vinci 系統的快速採用與使用。

  • Also during the quarter, we shipped a second system to the University of California Irvine, which has established a da Vinci-based urology training facility. And, for the first time, we shipped a third da Vinci system to a single facility. In this case, Hackensack University Medical Center. This brings to 11 the number of our customer sites having multiple da Vinci systems.

    此外,在本季我們也向加州大學爾灣分校(University of California Irvine)出貨了第二套系統,該校已建立以 da Vinci 為基礎的泌尿科訓練中心。並且,我們首次向單一機構出貨第三套 da Vinci 系統。在此案例中,是 Hackensack University Medical Center。這使得擁有多套 da Vinci 系統的客戶據點數量達到 11 個。

  • During the first quarter, we began commercial shipments for the da Vinci system fourth-arm upgrades. The clinical capabilities provided by the extra arm have been well-received by cardiac and general surgeons, as well as urologists performing da Vinci prostatectomies.

    在第一季期間,我們開始商業出貨 da Vinci 系統的第四臂升級套件。額外手臂所提供的臨床能力,已獲得心臟外科與一般外科醫師,以及執行 da Vinci 前列腺切除術的泌尿科醫師的高度肯定。

  • The fourth arm was featured at three of the four major medical conferences that we attended during the quarter. The conferences we attended were the Society of Thoracic Surgery, STS; [Sages], EUA-the European Association of Urology-and for the first time, IPEC-the International Pediatric [inaudible] surgery group.

    第四臂在本季我們參與的四大主要醫學會議中的三場被重點展示。我們參與的會議包括:胸腔外科學會(Society of Thoracic Surgery,STS)、[Sages]、EUA—歐洲泌尿科學會(European Association of Urology),以及首次參與的 IPEC—國際小兒[聽不清]外科團體。

  • The enthusiasm surrounding robotic surgery at these conferences was clear. With each passing conference, the momentum for minimally-invasive robotic surgery increases. At the STS, we built on the Intuitive Cardiac story by highlighting atrial septal defect repair-Intuitive's second [intracardiac] surgery clearance. At the scientific sessions, four films were shown, which featured robotic cardiac surgery with the da Vinci system.

    在這些會議上,圍繞機器人手術的熱度非常明顯。隨著每一場會議的推進,微創機器人手術的動能持續增強。在 STS,我們在 Intuitive 心臟外科的故事基礎上,強調了房間隔缺損修補—這是 Intuitive 第二項[心腔內]手術適應症核准。在科學議程中,播放了四部影片,展示使用 da Vinci 系統進行的機器人心臟手術。

  • Following the close of the congress exhibits, nearly 200 surgeons attended a reception we co-hosted with Johnson and Johnson's Cardio-Innovation Division, featuring an international panel of da Vinci system users presenting their techniques and results for several advanced cardiac procedures.

    在大會展覽結束後,近 200 位外科醫師參加了我們與嬌生(Johnson and Johnson)心臟創新事業部(Cardio-Innovation Division)共同主辦的招待會;會中由國際 da Vinci 系統使用者組成的專家小組,分享其在多項進階心臟手術中的技術與成果。

  • At the EAU in Madrid, which was attended by over 6,000 urologists, the da Vinci system ran nearly nonstop for three days, with test drives. Urologists, which traditionally have been slow to adopt laparascopy within their practice, visited our booth in large numbers to learn more about the da Vinci system. During the president's address, laparoscopy within urologist's practice was recognized as one of the two most-relevant movements currently taking place within the field of urology. Intuitive is well-positioned to play a prominent role within this movement.

    在馬德里的 EAU 會議上,超過 6,000 名泌尿科醫師與會,da Vinci 系統連續三天幾乎不停運轉,提供試用體驗。傳統上在其臨床實務中採用腹腔鏡較為緩慢的泌尿科醫師,大量造訪我們的攤位以進一步了解 da Vinci 系統。在主席致詞中,泌尿科實務中的腹腔鏡被認為是目前泌尿科領域正在發生的兩大最相關趨勢之一。Intuitive 已具備良好定位,可在此趨勢中扮演重要角色。

  • At [Sages]-the da Vinci system was once again well represented within the scientific sessions. Surgeons representing Ohio State University, University of Illinois Chicago and Johns Hopkins University provided clinical presentations of da Vinci. Live da Vinci systems surgeries, featuring gastric bypass procedure, were piped into both the Intuitive and the [Epicom] endosurgery booths.

    在 [Sages] 會議上,da Vinci 系統再次在科學議程中占有相當比重。來自俄亥俄州立大學、伊利諾大學芝加哥分校以及約翰霍普金斯大學的外科醫師,進行了 da Vinci 的臨床發表。以胃繞道手術為主題的 da Vinci 系統即時手術,也同步轉播至 Intuitive 與 [Epicom] 內視鏡外科攤位。

  • Also, Dr. [Mark Palomini] of Johns Hopkins called a special organizational session to discuss the notion of creating an organization to focus on robotics within general surgery. At the [IPEC] conference, which ran in parallel with [Sages], the interest for the da Vinci system was strong. The pediatric community, although small by numbers, is influential in stature, and has been moving toward robotics to address several unmet needs within their MIS practices. As I mentioned earlier, two prestigious children's hospitals purchased da Vinci systems during the quarter, while two additional units were sold to facilities in which pediatrics played a significant role. Overall, the Q1 tradeshow season was substantial in both content and sales leads. Surgeons continued to demonstrate the da Vinci system's clinical efficacy within general surgery, urology, cardiac surgery and now pediatric surgery.

    此外,約翰霍普金斯的 [Mark Palomini] 醫師召集了一場特別的組織會議,討論成立一個聚焦一般外科機器人技術的組織之構想。在與 [Sages] 同期舉行的 [IPEC] 會議上,對 da Vinci 系統的興趣也相當強烈。小兒外科社群雖然人數不多,但在地位與影響力上舉足輕重,並正朝向機器人技術發展,以滿足其微創手術(MIS)實務中若干尚未被滿足的需求。如我先前提到的,本季有兩家知名兒童醫院購買了 da Vinci 系統,另有兩套售出至小兒科扮演重要角色的醫療機構。整體而言,第一季的展會季在內容與銷售線索兩方面都相當可觀。外科醫師持續證明 da Vinci 系統在一般外科、泌尿科、心臟外科,以及如今的小兒外科中的臨床療效。

  • During the first quarter, we consummated a strategic alliance with Medtronic cardiac surgery. The cardiac industry's preeminent company. We are pleased to be allied with Medtronic toward the advancement of minimally-invasive and totally endoscopic beating-heart cardiac surgery. The agreement is framed around co-marketing, procedure development and training initiatives, as well as for the potential for co-product development. As part of our agreement, Intuitive will transfer ownership of its endo-stabilizer system to Medtronic, who will begin marketing the product in Europe-and following FDA clearance, within the United States.

    在第一季期間,我們與 Medtronic 心臟外科完成了一項策略聯盟。該公司是心臟產業中首屈一指的企業。我們很高興能與 Medtronic 攜手推動微創與全內視鏡、跳動心臟心臟手術的進展。本協議以共同推廣(co-marketing)、術式開發與訓練計畫為核心,並包含共同產品開發的可能性。依據協議內容,Intuitive 將把其內視鏡穩定器(endo-stabilizer)系統的所有權移轉給 Medtronic;Medtronic 將先在歐洲開始行銷該產品,並在取得 FDA 核准後於美國市場行銷。

  • In March, Dr. [Frank van Pratt] of [Ohls] Belgium, performed a multi-vessel small [thoracautomy] or MVST procedure, using the da Vinci system in concert with Medtronic's new Starfish NS, which was broadcast live into the general session of the cardio-thoracic techniques and technology conference in Miami. This MVST procedure holds promise for patients undergoing surgery for multi-vessel cardiac disease. This broadcast also represented the first of many co-marketing events between Intuitive and Medtronic.

    在三月,來自比利時 [Ohls] 的 [Frank van Pratt] 醫師,使用 da Vinci 系統並搭配 Medtronic 新款 Starfish NS,完成一項多血管小型[thoracautomy](MVST)手術,並在邁阿密舉行的心胸外科技術與科技會議全體大會中進行現場直播。此 MVST 手術對於接受多血管心臟疾病手術的患者具有潛在效益。這次直播也代表 Intuitive 與 Medtronic 眾多共同推廣活動中的第一場。

  • Also during the quarter, we began to market our new vision system. This new three-channel vision system was born out of our collaboration with Olympus Optical. The product provides the surgeon with the ability to toggle between a wide-angle two-dimensional view and a high-precision three-dimensional view, without every touching or adjusting the scope.

    此外在本季,我們開始行銷全新的視覺系統。這套新的三通道視覺系統源自我們與 Olympus Optical 的合作。該產品讓外科醫師能在廣角的二維視野與高精度的三維視野之間切換,而無需觸碰或調整鏡頭。

  • Also during [Sages], we featured a new surgical [annotator] for use with our da Vinci system. This surgical [annotator] was developed by [Striker] Communications and provides [illustration] capabilities to the da Vinci console surgeon from a proctoring or assistant surgeon. The surgical [annotator] has the potential to aide in the procedure-training pathway for complex, minimally-invasive surgery.

    同樣在 [Sages] 期間,我們展示了一款可搭配 da Vinci 系統使用的新型手術[註記器](surgical [annotator])。此手術[註記器]由 [Striker] Communications 開發,可讓指導醫師或助手外科醫師為 da Vinci 主控台外科醫師提供[圖示]標註功能。該手術[註記器]有潛力協助複雜微創手術的術式訓練流程。

  • That wraps up my comments on our activities and sales marketing and business development. SO With that, I will turn the time over to David Shaw.

    以上就是我對我們在活動、銷售行銷與業務開發方面的說明。因此,接下來我把時間交給 David Shaw。

  • David Shaw - VP Legal Affairs and Corporate Counsel

    David Shaw - VP Legal Affairs and Corporate Counsel

  • Thanks, Aleks. As Lonnie mentioned, I'd like to provide a little background on our panel litigation against [Brookhill Wilke], which I'll call [Wilke] for short, for now. In our comments calls, we don't normally comment on events or activities we don't believe have a likelihood of being material to our company. But we think there are enough questions on what this litigation actually is, so I'll say a few words, now. Hopefully, it'll put the suit into context and perspective.

    謝謝你,Aleks。如 Lonnie 所提到的,我想先就我們針對 [Brookhill Wilke](以下簡稱 [Wilke])所提起的陪審團審理訴訟,提供一些背景說明。在我們的電話會議中,我們通常不會評論我們認為不太可能對公司構成重大影響的事件或活動。但我們認為,外界對這起訴訟究竟是什麼有相當多疑問,因此我現在會簡要說明幾點。希望能讓大家對這起訴訟有更完整的脈絡與理解。

  • It's worth mentioning up front that we continue to view [Wilke's] suit as without merit on a number of different grounds, including that we believe we don't practice what [Wilke] claimed at intervention; for several different reasons. [Wilke] certainly did not invent auto-robotic surgery, since this idea came after much of the early work in the field by [SRI], IBM and others.

    值得先在一開始就提到的是,我們仍然認為[Wilke]的訴訟在多個不同的理由上都毫無根據,包括我們相信在介入時我們並未實施[Wilke]所主張的內容;而且原因不只一個。[Wilke]當然也沒有發明自動機器人手術,因為這個想法是在[SRI]、IBM及其他人在該領域完成許多早期工作之後才出現的。

  • As for a little of the history, [Wilke's] suit is in 2000 on essentially one main patent that identifies a Dr. Peter [Wilke] as the sole inventor. Dr. [Wilke] has over 200 patents to his name, that run the gamut from food processing and personal hygiene to medical tools and sporting techniques. The patent that he chose to assert against us concerns a particular remote surgery apparatus that separates the surgeon from the patient with various specific hardware.

    至於一些歷史背景,[Wilke]的訴訟是在2000年提出,基本上是圍繞一件主要專利,該專利將Peter博士[Wilke]列為唯一發明人。Wilke博士名下有超過200件專利,涵蓋範圍從食品加工與個人衛生到醫療工具與運動技術。他選擇用來對我們主張的那件專利,涉及一種特定的遠端手術裝置,透過各種特定硬體將外科醫師與病患分隔開來。

  • From all the defenses available to us, we selected one to support our first motion for summary judgment. In late 2001, the district court agreed with us and threw the suit out. Recently, the court repealed so the federal circuit reversed the district court's judgment, because they reached a somewhat different conclusion as to what two words in the claims actually mean. So that sent the case back for further proceedings.

    在我們可用的所有抗辯中,我們選擇其中一項來支持我們第一次提出的簡易判決動議。在2001年末,地方法院同意我們的主張並將訴訟駁回。最近,聯邦巡迴上訴法院推翻了地方法院的判決,因為他們對權利要求中兩個詞的實際含義得出了略有不同的結論。因此案件被發回進一步審理。

  • However, we believe that a fair reading of the appellate court opinion still supports our original non-infringing position. It allows us to continue to raise that defense with the district court on remand.

    然而,我們認為對上訴法院意見作出公平解讀,仍然支持我們原先的不侵權立場。這也使我們得以在發回重審後,繼續在地方法院提出該項抗辯。

  • In addition and as necessary, we'll continue to apply all of our other defenses to this patent. Including that we believe we don't infringe for several other reasons, the patent isn't valid on several grounds, and that it's unenforceable as prosecuted. At this point, we believe the patent suit is in essence not much more than a distraction and an unfortunate part of the cost of doing business in this space.

    此外,視需要而定,我們將繼續對該專利主張所有其他抗辯。其中包括:我們相信基於其他幾個理由我們並未侵權;該專利在多個方面無效;以及其在申請/審查過程中存在使其不可執行的問題。就目前而言,我們認為這起專利訴訟本質上不過是一種干擾,也是我們在此領域經營所不得不承擔的一項不幸成本。

  • Shifting gears, now. In connection with the [Moser] agreement with Computer Motion. I'm happy to announce as Lonnie already indicated, that we are no longer fighting patent battles on the forefronts we were. All patent disputes with Computer Motion are now either on hold or are in a period of inactivity, pending closure of the merger. Should the merger consummate, all will be terminated. Our merger agreement has allowed both companies to refocus all of their efforts on what counts the most. Our customers, their patients, and improving the quality of minimally-invasive surgical care.

    現在換個話題。關於與Computer Motion之間的[Moser]協議。我很高興宣布,正如Lonnie先前所指出的,我們已不再在先前那些前線上進行專利戰。目前與Computer Motion的所有專利爭議都已暫停或處於不活躍狀態,等待併購完成交割。若併購完成,所有爭議都將終止。我們的併購協議使兩家公司都能重新聚焦於最重要的事情。也就是我們的客戶、他們的病患,以及提升微創手術照護的品質。

  • We believe the proposed merger and its benefits are a very positive step for both companies, and we look forward to being able to put the companies together at the end of June, after we have the required approvals.

    我們相信擬議中的併購及其效益,對兩家公司而言都是非常正面的一步;在取得所需核准後,我們也期待能在六月底將兩家公司整合在一起。

  • Thanks for listening; and now I'll turn the rest back to Lonnie.

    感謝各位收聽;接下來我把剩下的時間交還給Lonnie。

  • Lonnie Smith - President and CEO

    Lonnie Smith - President and CEO

  • That concludes our presentation. We'll now open the floor to any questions you might have.

    我們的簡報到此結束。接下來我們將開放現場,回答各位可能有的問題。

  • Operator

    Operator

  • At this time, if you do have a question, please press star-1 on your touchtone phone. You will be announced prior to asking your question. Once again, that is star-1 on your touchtone phone to ask a question.

    此時若您有問題,請在您的按鍵式電話上按星號1。在您提問之前,系統會先報出您的姓名。再次提醒,若要提問,請在您的按鍵式電話上按星號1。

  • Sheetal Mehta from Bear Stearns, you may ask your question.

    Bear Stearns的Sheetal Mehta,您可以提問。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • Good afternoon. Just a couple of quick questions. Can you remind me where in the revenues you record the fourth-arm sales? Is that in Systems? Or is that in Instruments and Accessories?

    午安。我有幾個簡短問題。

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • That's in Systems.

    是在系統(Systems)。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • It's in Systems. So does the inclusion of that revenue in the Systems what propels the higher average selling price? Or did the actual system have a price increase, there?

    是在系統(Systems)。那麼把這部分收入納入系統(Systems),是否就是推升平均售價(ASP)較高的原因?還是系統本身有調漲價格?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Sheetal, this is Ben. Yes. The fourth-arm sales did help increase the ASP, there. But also, we had a pretty high proportion of sales in the United States this quarter.

    Sheetal,我是Ben。是的。第四支手臂的銷售確實有助於提高ASP。不過另外一點是,本季我們在美國的銷售占比相當高。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • Okay. Thank you. Can you remind me if there was an actual increase on list price in 2003, to the system?

    好的,謝謝。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • From 2002 to 2003, yes. There was an increase in the list price.

    從2002到2003,有。牌價確實有上調。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • Can you quantify that?

    可以量化一下嗎?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • It increased by about $30,000.

    大約上調了30,000美元。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • Second question is just a housekeeping item. The deferred compensation and amortization line. Can you quantify that? Does that come just from SG&A? If I pull that out?

    第二個問題是一些帳務上的事項。遞延薪酬與攤銷那一行。可以量化一下嗎?那是完全來自SG&A嗎?如果我把它剔除的話?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Let me just kind of repeat what we said last quarter on this, Sheetal. I just want to remind you that last quarter what we mentioned was that there was $200,000 left in deferred compensation to be amortized over the first two quarters of this year. That is still the case.

    Sheetal,我先重申一下我們上季對此的說明。提醒你,上季我們提到尚有20萬美元的遞延薪酬,將在今年前兩季攤銷。目前仍是如此。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • Over the first two quarters?

    在前兩季?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Yes.

    是的。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • Then just in terms of R&D spending. You mentioned the end of clinical activity, going forward. Is this less than 18% of sales something that we should expect, going forward?

    接著關於研發支出。你提到臨床活動的結束,往後來看。研發低於銷售額的18%,是否是我們往後應該預期的水準?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • We mentioned that we dropped that year-over-year. We were running three heart trials, last year. We now have two of those cleared by the FDA, and we're running. That number is now containing one of our heart trials. Where we go in the future, we have not guided yet, at this point.

    我們提到這個比率年對年下降。去年我們同時進行三項心臟試驗。現在其中兩項已獲FDA核准並在進行中。目前這個數字只包含我們其中一項心臟試驗。至於未來會如何走向,我們目前尚未提供指引。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • My final question is, if I look at the number of units I had projected for 2003, just again-da Vinci systems. I had 68 projected for this year. Would you say that that's still doable? Given the run rate that we've got right now?

    我最後一個問題是,如果我看我對2003年的出貨量預估,仍然是指da Vinci系統。我預估今年是68台。以我們目前的出貨/銷售節奏來看,你會說這仍然可達成嗎?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Yes, Sheetal, this is Ben. I'm going to go back to our guidance on revenue. We had given you guidance on revenue for Intuitive as a standalone company of $85-100 million. That was [gross] of 20-40% over last year. We're still staying with that guidance.

    是的,Sheetal,我是Ben。我會回到我們對營收的指引。我們先前給出的指引是,Intuitive作為獨立公司,營收為8,500萬至1億美元。這相當於較去年成長20%到40%(以[總額]計)。我們仍維持該指引不變。

  • Sheetal Mehta - Analyst

    Sheetal Mehta - Analyst

  • Thank you.

    謝謝。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • You bet.

    不客氣。

  • Operator

    Operator

  • Charles Olsziewski with UBS. You may ask your question.

    UBS的Charles Olsziewski,您可以提問。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay.

    好的。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Was that me? I don't know.

    那是我嗎?我不知道。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • A couple of things. As far as the guidance you gave last quarter regarding the outlook for gross margins of mid-50s. You're essentially in the mid-50s here in the first quarter. Does that essentially mean you're ahead of where you thought you'd be? Or should we look for sort of a flattish number throughout the year-although the recurring revenue [change] is probably going to climb?

    有幾點。就你們上季針對毛利率約在 50% 中段的展望所給的指引而言。你們第一季基本上就已經在 50% 中段了。這是否意味著你們其實比原先預期更超前?還是我們應該預期全年大致持平——雖然經常性收入的[變化]可能會上升?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • I guess I'll take a shot at that, Charlie. I think you recall last quarter, we mentioned that we had some gross margin improvement due to improved reliability in the field.

    Charlie,我想我先回答一下。我想你記得上季我們提到,因為現場可靠性提升,我們的毛利率有所改善。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Correct.

    沒錯。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • We continued to experience that in the first quarter, as well. As a result, we're booking less warranty reserves.

    第一季我們也持續看到同樣的情況。因此,我們提列的保固準備較少。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Correct.

    沒錯。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • We hope that that will continue. But I think that's something that we can't necessarily count on, going forward. So we're still going to stick with the mid-50s, in terms of gross margin at this point.

    我們希望這能持續。但我認為這不是我們未來一定能依賴的事情。所以就目前而言,我們在毛利率方面仍會維持 50% 中段的看法。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • As far as the credit to SG&A, I guess that you've essentially recovered half of what was pilfered. Is that a good way to look at it?

    至於對 SG&A 的抵減,我想你們基本上已經追回了被盜取金額的一半。這樣理解對嗎?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • That is.

    是的。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Laughing.

    (笑)

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • In other words, we were insured for about half of what was pilfered.

    換句話說,我們的保險大約涵蓋了被盜取金額的一半。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • So the other half you probably won't get back?

    所以另外一半你們大概拿不回來?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • That's correct.

    沒錯。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • We are pursuing legal channels on the other portion. Time will tell whether we're able to recover anything, or not.

    另一部分我們正在透過法律途徑追討。能否追回任何金額,還要看後續發展。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • As far as the first quarter is concerned, it's clear. I guess you announced your pending union with Computer Motion on March 7th. Obviously, there were discussions for some period of time leading up to that announcement. Were you expecting to spend more in legal in the first quarter than you ultimately did, given your discussions? In other words, if this merger weren't announced, would you have spent more money on legal than you ultimately did?

    就第一季而言,這點很清楚。我想你們在 3 月 7 日宣布與 Computer Motion 的合併案正在進行中。顯然在公告之前,你們已經討論了一段時間。鑑於這些討論,你們原本是否預期第一季的法律費用會比實際發生的更多?換句話說,如果沒有宣布這項合併,你們在法律費用上是否會花得比實際更多?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Yes.

    是的。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • A significant amount or insignificant?

    是很多還是不多?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Significant.

    很多。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • The rate we were spending, it definitely was significant.

    以我們當時的花費速度來看,確實是相當可觀。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Then as far as Medtronic, Aleks. Have they started selling the product in Europe, yet? Or is it still kicking off?

    那再談 Medtronic,Aleks。他們開始在歐洲銷售該產品了嗎?還是仍在啟動階段?

  • Aleks Cukic - VP Business Development and Strategic Planning

    Aleks Cukic - VP Business Development and Strategic Planning

  • They have not. There are a few final tests that are required in order for them to begin selling the product in Europe.

    還沒有。他們要在歐洲開始銷售該產品,還需要完成幾項最後的測試。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay. Thanks.

    好的。謝謝。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Thank you, Charlie.

    謝謝你,Charlie。

  • Operator

    Operator

  • Brian Gagnon (ph) with Gagnon Securities. You may ask your question.

    Gagnon Securities 的 Brian Gagnon(音)。你可以提問。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • Hi. I've got three questions for you. The first is, did the third arm finally start shipping?

    嗨。我有三個問題。第一個是,第三支手臂終於開始出貨了嗎?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Fourth.

    第四支。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Fourth arm.

    第四支手臂。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • Fourth. I lose track of my arms.

    第四支。我都搞不清我有幾支手臂了。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Yes, it has. It did. Yes.

    是的,已經開始了。確實開始了。是的。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • How many did you actually ship in the quarter?

    這一季你們實際出貨了多少?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • We sold one fourth arm in the fourth quarter, [Brian].

    我們在第四季賣出了一支第四手臂,[Brian]。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • So is Hackensack a Q2 event?

    所以 Hackensack 會是在第二季發生的事嗎?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • One of those was Hackensack. The others are coming.

    其中一支就是 Hackensack。其他的還在後面。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • Deferred revenue line item went up quite a bit. Can you tell us what that was all about?

    遞延收入這個科目增加了不少。可以說明一下原因嗎?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Yes. Deferred revenue is a place where we also record or mostly record our deferred service revenue. And we've described in the past, when a customer buys a system, there's a one-year warranty. Following that, service revenue kicks in. So typically, what you're going to see is that deferred revenue item will kick up, as you know, a larger and larger [inaudible]. That's really what's driving that.

    可以。遞延收入也是我們記錄(或主要記錄)遞延服務收入的地方。我們過去也說明過,客戶購買系統時會有一年保固。之後才開始認列服務收入。所以通常你會看到遞延收入項目會往上跳,因為你知道,會有越來越大的[聽不清]。主要就是這個因素在推動。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • Actually, I lied; I've got two other questions. The operating expenses, going forward. Now that this Computer Motion issue is temporarily behind you-can you give us an idea of what the ongoing operating expenses might look like?

    其實我剛剛說錯了;我還有另外兩個問題。關於未來的營業費用。現在 Computer Motion 這件事暫時告一段落——你們能否讓我們了解一下,後續持續性的營業費用大概會是什麼樣子?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Yes. I guess the best way for us to describe us is this, [Brian]. We had given some guidance that from last year to this year, operating expenses were going to grow by 5% or less. So as a standalone company and the things that we've done, that's still true. Now With the combined company, we can't give comment on. But we're doing the best to make sure we get to profitability by the fourth quarter.

    可以。我想我們最好的說法是這樣,[Brian]。我們曾給過一些指引,從去年到今年,營業費用成長將在 5% 或以下。以獨立公司來看,以及我們所做的事情,這點仍然成立。至於合併後的公司,我們無法評論。但我們會盡最大努力,確保在第四季達到獲利。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • But if I look at the $13.6 million you had in operating expenses this quarter-down a million-should we expect that in Q2 that those numbers should remain stable, go down or go up?

    但如果我看你們本季的營業費用是 1,360 萬美元——比之前少了 100 萬——我們是否應該預期第二季這些數字會維持穩定、下降,還是上升?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Again, [Brian], we're going to have to iterate on the year, which is year-over-year as a standalone. Then you're looking at the 5% reduction.

    再說一次,[Brian],我們必須以年度迭代來看,也就是以獨立公司口徑的年對年。那你看到的就是 5% 的降幅。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • The last question is what are you pricing the fourth arm at, at this point?

    最後一個問題是,目前第四手臂的定價是多少?

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • We're not going to give that out at this point, [Brian]. We'd be giving that out at a later time.

    我們目前不會對外提供這個資訊,[Brian]。我們會在之後的時間再公布。

  • Brian Gagnon - Analyst

    Brian Gagnon - Analyst

  • Good. Thanks very much.

    好的。非常感謝。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Okay.

    好的。

  • Operator

    Operator

  • Just as a reminder, if you do have a question, please press star-1 on your touchtone phone. Mark Smillie, you may ask your question.

    提醒一下,如果你有問題,請在按鍵式電話上按星號 1。Mark Smillie,你可以提問。

  • Mark Smillie - Analyst

    Mark Smillie - Analyst

  • Great. Thanks. Good afternoon, everybody.

    很好。謝謝。各位下午好。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • Mark.

    Mark。

  • Mark Smillie - Analyst

    Mark Smillie - Analyst

  • Quick question. You guys are going AUA this year. What are you guys looking at for that show? Is it a big show for you? Do you expect a lot of interest to come out of that? What are the highlights of the show that you're looking at, this year?

    簡單問一下。你們今年會去 AUA。你們對那個展會有什麼期待?那對你們來說是個大型展會嗎?你們預期會引起很多關注嗎?今年你們關注的展會亮點是什麼?

  • Aleks Cukic - VP Business Development and Strategic Planning

    Aleks Cukic - VP Business Development and Strategic Planning

  • Yes, Mark; this is Aleks. We definitely view the AUA as an important show for us, on many levels. What do we expect there? There will be a few live surgeries that will be piped into our booth. There are a number of clinical presentations and poster sessions that will include I think some very favorable evidence-based medicine for da Vinci, with respect to radical prostatectomies. There will be approximately, I think we're expecting somewhere on the order of 10,000-11,000 urologists there from all over the world.

    是的,Mark;我是Aleks。我們確實將AUA視為對我們而言在多個層面都很重要的一場展會。我們在那裡期待什麼?會有幾場現場手術會被轉播到我們的攤位。也會有多場臨床報告與海報展示,我認為其中會包含一些對達文西(da Vinci)在根除性前列腺切除術方面相當有利、以實證醫學為基礎的證據。預計大約會有一萬到一萬一千名來自世界各地的泌尿科醫師參加。

  • We definitely see this as an important show. There will be a fourth-arm system there, and if the EAU in Europe, which is really a precursor to the show, is any indication, our systems are going to be very busy with test [runs].

    我們確實認為這是一場重要的展會。現場會有第四臂系統;而如果歐洲的EAU(這其實是該展會的前哨)可作為任何指標的話,我們的系統將會因為試用(test [runs])而非常忙碌。

  • Mark Smillie - Analyst

    Mark Smillie - Analyst

  • Great. Thank you.

    很好。謝謝你。

  • Operator

    Operator

  • Charles Olsziewski, you may ask your question.

    Charles Olsziewski,您可以提問。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Yes. A follow-up. Susan-maybe I heard you wrong. Did I hear you say that you actually had a headcount reduction of 18 quarter to quarter?

    是的。我有個追問。Susan——也許是我聽錯了。我是否聽到你說,你們的人員編制(headcount)從上一季到這一季實際減少了18人?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Yes, you did.

    是的,你沒聽錯。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Correct me if I'm wrong. Is that the first? Certainly I don't remember a time as you've grown where your headcount has declined.

    如果我沒弄錯的話。這是第一次嗎?至少在你們成長的過程中,我不記得有任何時候你們的人員編制曾經下降。

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • That's correct, Charlie. We've always been building our sales force and field operations group. We've talked earlier that we would reach a point where we stopped being able to leverage that.

    沒錯,Charlie。我們一直在擴建銷售團隊與外勤營運團隊。我們先前也談過,我們會到達一個點,屆時就無法再持續從這方面取得槓桿效益。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • That's just an outgrowth of the leverage?

    所以這只是槓桿效益延伸出來的結果?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Yes.

    是的。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Thanks.

    謝謝。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • We'll take one more question, and close the meeting.

    我們再接最後一個問題,然後結束會議。

  • Operator

    Operator

  • Our final question comes from [Larry Hemovitch]. You may ask your question.

    我們最後一個問題來自[Larry Hemovitch]。您可以提問。

  • Larry Hemovitch - Analyst

    Larry Hemovitch - Analyst

  • Good afternoon. Perhaps asking Charlie Olsziewski's question a different way. Susan, were there any expenses incurred during the quarter as a result of the negotiations and the Computer Motion announcement that were significant, relative to the ongoing legal expenses that you were incurring, with regard to the [inaudible]?

    下午好。也許用不同方式來問Charlie Olsziewski的問題。Susan,本季因為談判以及Computer Motion的公告,是否產生了任何相對於你們持續發生的法律費用而言、屬於重大(significant)的費用?就[聽不清]那部分而言?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • No. As we said on a previous call, we do anticipate merger expenses. That will be significant.

    沒有。如同我們在先前的電話會議所說,我們確實預期會有併購費用。那將會相當可觀。

  • Larry Hemovitch - Analyst

    Larry Hemovitch - Analyst

  • Right. They weren't in the first quarter.

    了解。第一季沒有包含那些費用。

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Those are capitalized as part of purchasing accounting.

    那些會依購買會計(purchase accounting)作為資本化處理的一部分。

  • Larry Hemovitch - Analyst

    Larry Hemovitch - Analyst

  • So we didn't see anything that would have affected the first quarter bottom line in that regard?

    所以就這方面而言,我們沒有看到任何會影響第一季損益底線的事項?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • That's correct.

    沒錯。

  • Larry Hemovitch - Analyst

    Larry Hemovitch - Analyst

  • I'm wondering, given that when companies that have been competing merge, if there were any impacts you saw in the selling cycle in the quarter. Did people have some hesitancy, perhaps, in closing deals? During the last month of the quarter, I'm sure you do more than 1/3 of your quarter. Because of any merger uncertainties at all. Can you comment on that? Do you think you would've done better, I guess, on the top line if the merger had not been done?

    我想問的是,鑑於競爭公司合併時,是否會對本季的銷售週期造成任何影響。客戶是否可能在成交上有些猶豫?在本季最後一個月,我相信你們的業績通常會超過全季的三分之一。是否因為任何併購不確定性而受到影響?你能評論一下嗎?我想問的是,如果沒有進行這次合併,你們的營收(top line)是否可能會更好?

  • Lonnie Smith - President and CEO

    Lonnie Smith - President and CEO

  • Larry, this is Lonnie. I won't comment on whether we would've done better or worse, but I will say that when something like this occurs, it does cause greater uncertainty. Certainly, I believe and know of medical centers that delayed their purchase decision until we became more explicit and it becomes clearer in terms of what this merger means. So definitely, it does impact the market.

    Larry,我是Lonnie。我不評論我們會做得更好或更差,但我會說,當這類事情發生時,確實會造成更大的不確定性。我確實相信並且也知道有些醫療中心延後了採購決策,直到我們更明確、也更清楚說明這次合併的意義。所以毫無疑問,這會影響市場。

  • Larry Hemovitch - Analyst

    Larry Hemovitch - Analyst

  • Yes. Hopefully that all resolves itself as you go into the second half and the deal's done.

    是的。希望當你們進入下半年、交易完成後,一切都能解決。

  • Lonnie Smith - President and CEO

    Lonnie Smith - President and CEO

  • I think it clearly will. But for this period of time-from the time of announcement 'til the deal is closed, there is uncertainty in the market, and a lot of noise that both companies are living with.

    我認為很明顯會的。但在這段期間——從公告發布到交易完成——市場存在不確定性,兩家公司都必須承受許多雜音。

  • Larry Hemovitch - Analyst

    Larry Hemovitch - Analyst

  • Lonnie or maybe Susan, aside from SEC delays or any SEC issues, is there anything else that could likely change the date that you'd suggested as the closing date in any material way?

    Lonnie或Susan,除了SEC延遲或任何SEC相關議題之外,還有其他可能會在重大程度上改變你們所建議的交割日期的因素嗎?

  • Susan Barnes - Senior VP and CFO

    Susan Barnes - Senior VP and CFO

  • Larry, as I said before, we are waiting for the SEC to review our S4, and then we will anticipate the next part of the calendar is the proxy mailing for shareholder votes. Those two issues will be ahead of us. Again, that's why we're sticking with the end of the quarter guidance we gave you before.

    Larry,如我之前所說,我們正在等待SEC審閱我們的S-4,接著我們預期下一個時程是寄發委託書(proxy)以進行股東投票。這兩件事都還在我們前面。同樣地,這也是為什麼我們仍維持先前給你的指引:在本季末完成。

  • Larry Hemovitch - Analyst

    Larry Hemovitch - Analyst

  • Thanks very much.

    非常感謝。

  • Benjamin Gong - VP, Treasurer and Corporate Controller

    Benjamin Gong - VP, Treasurer and Corporate Controller

  • That was our last question for today. To again summarize the highlights of the first quarter-we recorded revenue of $19.2 million; up 33% from prior year. We shipped 14 da Vinci Surgical Systems, ending the quarter with 163 systems installed worldwide. We grew recurring revenue to $5.4 million-up 103% from prior year. We improved our gross margin to 54.6%, up from 47.9%. We recorded our smallest quarterly loss, at $2.3 million. That's going public. We signed an agreement with Medtronic, aimed at advancing minimally-invasive beating-heart surgery. We released several new products for sale and shipment, including a fourth arm for the da Vinci Surgical System. And we made significant progress in our planning for a post-merger transition with Computer Motion.

    以上是我們今天最後一個問題。再次總結第一季的重點——我們的營收為1,920萬美元;較去年同期成長33%。我們出貨14套達文西(da Vinci)手術系統,季末全球安裝量達163套。我們的經常性收入成長至540萬美元——較去年同期成長103%。我們的毛利率提升至54.6%,高於47.9%。我們錄得史上最小的單季虧損,為230萬美元。這就是上市公司。我們與Medtronic簽署協議,旨在推進微創的跳動心臟手術。我們發布了數項可供銷售與出貨的新產品,包括達文西手術系統的第四臂。此外,我們在與Computer Motion合併後的過渡規劃方面也取得重大進展。

  • That concludes today's call. We thank you for your participation.

    今天的電話會議到此結束。感謝各位的參與。

  • Operator

    Operator

  • Thank you. You may disconnect at this time.

    謝謝。您現在可以斷線。